NCT02300467View on ClinicalTrials.gov

NOV120401 (CKD-516 Tablet) for Advanced Solid Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Advanced Refractory Solid Tumors
Interventions
DRUG

NOV120401

5 to 45 mg/day PO for 5 consecutive days and 2 days off

Trial Locations (1)

410-769

RECRUITING

National Cancer Center, Goyang-si

Sponsors
All Listed Sponsors
collaborator

Chong Kun Dang Pharmaceutical

INDUSTRY

lead

National OncoVenture

OTHER